Jump to content

Cuban Anti-Cancer Vaccine to be Tested in Malaysia

Recommended Posts

http://www.plenglish.com/article.asp?ID ... 7FC7199%7D)&language=EN

Kuala Lumpur, Mar 29 (Prensa Latina) A therapeutic anti-cancer vaccine developed by Cuban scientists is to be clinically tested here, reported Bernama news agency on Thursday.

The vaccine is expected to give new hopes for patients in the advanced stage of lung cancer in terms of a longer survival rate and better quality of life.

The vaccine, discovered by Dr Gisela Gonzalez Marinello of the Centre of Molecular Immunology in Cuba in 1992, will be clinically trial-tested in Malaysia for the first time.

Gonzalez, who is also its project manager, said 230 advanced stage lung cancer patients had been identified in 12 hospitals to participate in the clinical tests in what could be a landmark trial for the drug.

Based on previous clinical trials in Cuba, Canada and the United Kingdom, the vaccine had demostrated its ability to promote longer survival rates of up to six months, and up to two years in some cases, while helping to improve the quality of life among lung cancer patients who responded to the vaccine.

She told Bernama in an interview here that the vaccine was safe, had no prolonged side effects and could be used in tandem with chemotheraphy and radiotherapy.

The Cuban doctor stressed the vaccine was not a cure for cancer but helps to fight against the growth of cancerous cells, adding that it was administered through monthly injections on four different parts of a patient's body.

Set to begin in May, the clinical trial in Malaysia is expected to take about two-and-a-half years and is being sponsored by Bioven Sdn Bhd, a local company specializing in advanced technology and life sciences.

Bioven chief executive officer Dr W. Shermal Perera, who was present at the interview, said the clinical trial would be monitored by the Cancer Research Centre of the Kuala Lumpur Hospital.

"This clinical trial in Malaysia is important to us because the data collected will be used to penetrate Europe and other countries," he said.

Bioven has the intellectual property rights for the vaccine here and in Southeast Asia.

Dr Perera said: "We have bought the licence and the patent has been assigned to us. We have the rights for Europe, Australia, Japan and New Zealand as well."

"In Malaysia, we hope to get it approved and registered within the next three years," he added. He said if the clinical trials went well, Malaysia would become the second country after Cuba to have the drug.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.